On Nov 07, major Wall Street analysts update their ratings for $Gilead Sciences (GILD.US)$, with price targets ranging from $95 to $105.
J.P. Morgan analyst Chris Schott maintains with a buy rating, and adjusts the target price from $100 to $105.
Barclays analyst Carter Gould maintains with a hold rating, and adjusts the target price from $76 to $95.
Wells Fargo analyst Mohit Bansal maintains with a buy rating, and maintains the target price at $105.
Jefferies analyst Michael Yee maintains with a buy rating, and maintains the target price at $105.
TD Cowen analyst Tyler Van Buren maintains with a buy rating, and adjusts the target price from $85 to $95.
Furthermore, according to the comprehensive report, the opinions of $Gilead Sciences (GILD.US)$'s main analysts recently are as follows:
The company experienced a sales surge, bolstered by robust performance across its HIV product range and revenues for Veklury surpassing expectations. The company's HIV segment demonstrated vigor this quarter, marked by sustained volume expansion and a positive product mix.
The company showcased a stronger than anticipated performance in Q3, bolstered not only by Veklury but also by Biktarvy.
Gilead has exhibited a 'consistent steady performance' this quarter, demonstrating the enduring robustness of its HIV franchise. This reliable strength is seen as a positive sign in advance of the company's forthcoming U.S. submission of lenacapavir for PrEP.
The firm noted that another solid quarter was recorded and mentioned that the revised target is mainly due to the anticipation that the Sunlenca PrEP opportunity, along with Livdelzi in PBC, may present new commercial prospects.
Gilead's recent financial results exceeded expectations, propelled by strong performance in its HIV segment and significant contributions from Veklury, coupled with lower operational expenses than anticipated. Additionally, the company's management has expressed optimism regarding the PrEP launch and forthcoming ASH data.
Here are the latest investment ratings and price targets for $Gilead Sciences (GILD.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月7日，多家華爾街大行更新了$吉利德科學 (GILD.US)$的評級，目標價介於95美元至105美元。
摩根大通分析師Chris Schott維持買入評級，並將目標價從100美元上調至105美元。
巴克萊銀行分析師Carter Gould維持持有評級，並將目標價從76美元上調至95美元。
富國集團分析師Mohit Bansal維持買入評級，維持目標價105美元。
富瑞集團分析師Michael Yee維持買入評級，維持目標價105美元。
TD Cowen分析師Tyler Van Buren維持買入評級，並將目標價從85美元上調至95美元。
此外，綜合報道，$吉利德科學 (GILD.US)$近期主要分析師觀點如下：
公司經歷了銷售激增，得益於HIV產品區間的強勁表現，Veklury的收入超出預期。公司的HIV業務板塊本季展現出活力，持續擴大了成交量，並有積極的產品組合。
公司在第三季度展現出比預期更強勁的表現，不僅得益於Veklury，還得益於Biktarvy。
吉利德在本季度展現出『穩健的持續表現』，展示了其HIV業務的持久強勁性。這種可靠的實力被視爲公司即將在美國提交lenacapavir用於PrEP的積極跡象。
該公司指出，又一個穩健的季度已被記錄，並提到修訂後的目標主要是因爲預計Sunlenca PrEP機會，以及PBC中的Livdelzi，可能帶來新的商業前景。
吉利德最近的財務結果超出了預期，得益於其HIV業務板塊的強勁表現，以及Veklury的重要貢獻，再加上預期之外的較低運營開支。此外，該公司管理層對PrEP的推出和即將公佈的ASH數據表達了樂觀情緒。
以下爲今日9位分析師對$吉利德科學 (GILD.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
